

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Trastuzumab

INITIATION – Early breast cancer

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- The patient has early breast cancer expressing HER 2 IHC 3+ or ISH+ (including FISH or other current technology)
- and
- Maximum cumulative dose of 106 mg/kg (12 months' treatment)
- and
- 9 weeks' concurrent treatment with adjuvant chemotherapy is planned
- or
- 12 months' concurrent treatment with adjuvant chemotherapy is planned
- or
- 12 months' sequential treatment following adjuvant chemotherapy is planned
- or
- 12 months' treatment with neoadjuvant and adjuvant chemotherapy is planned
- or
- Other treatment regimen, in association with adjuvant chemotherapy, is planned

INITIATION – metastatic breast cancer (trastuzumab-naïve patients)

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology)
- and
- The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer
- or
- The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance
- and
- The cancer did not progress whilst on lapatinib
- and
- Trastuzumab will not be given in combination with pertuzumab
- or
- Trastuzumab to be administered in combination with pertuzumab
- and
- Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer
- and
- The patient has good performance status (ECOG grade 0-1)
- and
- Trastuzumab not to be given in combination with lapatinib
- and
- Trastuzumab to be discontinued at disease progression

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Trastuzumab - continued

INITIATION – metastatic breast cancer (patients previously treated with trastuzumab)

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology)

and

The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer

or

The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance

and

The cancer did not progress whilst on lapatinib

and

Trastuzumab will not be given in combination with pertuzumab

or

Trastuzumab to be administered in combination with pertuzumab

and

Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer

and

The patient has good performance status (ECOG grade 0-1)

and

Trastuzumab not to be given in combination with lapatinib

and

Trastuzumab to be discontinued at disease progression

CONTINUATION – metastatic breast cancer

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology)

and

The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab

and

Trastuzumab not to be given in combination with lapatinib

and

Trastuzumab to be discontinued at disease progression

I confirm that the above details are correct:

Signed: Date: